162 related articles for article (PubMed ID: 17280505)
1. Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers.
Huang CL; Yokomise H; Miyatake A
Future Oncol; 2007 Feb; 3(1):83-93. PubMed ID: 17280505
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of p53 in non-small-cell lung cancer.
Komiya T; Hirashima T; Kawase I
Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
[TBL] [Abstract][Full Text] [Related]
3. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
[TBL] [Abstract][Full Text] [Related]
4. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
[TBL] [Abstract][Full Text] [Related]
5. [Gene therapy with tumor suppressor gene p53 and(or) p16 on the nude mice models of NSCLC in vivo].
Wu W; Zhang X; Qi X
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Jul; 23(7):403-5. PubMed ID: 11778504
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy of p16, p53 and p21 genes on the proliferation of lung cancer cells in vitro].
Wen G; Li J; Zou G; Fan X; Rao W
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):169-72. PubMed ID: 11812373
[TBL] [Abstract][Full Text] [Related]
7. New horizons: gene therapy for cancer.
Baselga J
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S39-42. PubMed ID: 10630368
[TBL] [Abstract][Full Text] [Related]
8. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers.
Ebina M; MartÃnez A; Birrer MJ; Ilona Linnoila R
Oncogene; 2001 May; 20(20):2579-86. PubMed ID: 11420668
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
Kagawa S; Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.
Apostolopoulou K; Pateras IS; Evangelou K; Tsantoulis PK; Liontos M; Kittas C; Tiniakos DG; Kotsinas A; Cordon-Cardo C; Gorgoulis VG
J Pathol; 2007 Nov; 213(3):294-302. PubMed ID: 17907153
[TBL] [Abstract][Full Text] [Related]
14. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
[TBL] [Abstract][Full Text] [Related]
15. [The p53 gene and protein in bronchial carcinogenesis:from biological to clinical aspects].
Zalcman G; Trédaniel J; Lechapt E; Lubin R; Soussi T; Hirsch A
Rev Mal Respir; 1994; 11(5):455-72. PubMed ID: 7816989
[TBL] [Abstract][Full Text] [Related]
16. [Topographic genomapping of p53 mutations in non-small cell lung cancer using in situ PCR].
Ebina M; Linnoila RI; Nukiwa T
Gan To Kagaku Ryoho; 1997 Feb; 24(4):406-11. PubMed ID: 9063476
[TBL] [Abstract][Full Text] [Related]
17. [Molecular therapy for human cancer with tumor suppressor p53 gene transfer].
Fujiwara T; Inoue F; Tanaka N
Gan To Kagaku Ryoho; 1998 Jan; 25(2):194-200. PubMed ID: 9474928
[TBL] [Abstract][Full Text] [Related]
18. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
19. E1B-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence of apoptosis.
Harada N; Maniwa Y; Yoshimura M; Nagata M; Hamada H; Yokono K; Okita Y
Oncol Rep; 2005 Nov; 14(5):1155-63. PubMed ID: 16211279
[TBL] [Abstract][Full Text] [Related]
20. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
